Tevogen Bio Reports First Quarter 2024 Financial Results
29 mai 2024 08h00 HE
|
Tevogen Bio Inc
Tevogen Bio first quarter '24 financial results: Liability elimination of $94.9M. $11.3M of net income. Net cash operations $2.1M. $36M LOC.
Global Engineered T Cells Market Forecast to 2028: Expansion into Solid Tumor Treatment, Advanced Combination Therapies, and Precision Gene-Edited T Cell Therapies
15 mai 2024 03h26 HE
|
Research and Markets
Dublin, May 15, 2024 (GLOBE NEWSWIRE) -- The "Engineered T Cells Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F" report has been added to ResearchAndMarkets.com's...
T Cell Therapy Pipeline Insight Report 2024
18 avr. 2024 11h34 HE
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "T cell therapy - Pipeline Insight, 2024" has been added to ResearchAndMarkets.com's offering.The report covers comprehensive insights of present...
Metastatic Liver Cancer Pipeline Insight 2024, Featuring Key Players Oncorus, Sirnaomics, Codiak BioSciences, RemeGen, Amarin, Medivir, AstraZeneca, Amal Therapeutics and Boehringer Ingelheim
15 avr. 2024 07h20 HE
|
Research and Markets
Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Liver Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides...
Anti-CD279 (PD-1) Antibody Drug Pipeline Research Report 2024: Insights on 40+ Companies Featuring GlaxoSmithKline, Innovent Biologics, BeiGene, and Shanghai Junshi Biosciences
11 avr. 2024 09h15 HE
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Anti-CD279 (PD-1)...
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
11 avr. 2024 08h05 HE
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Global CAR-T Cell Therapy Market Expected to Surge to USD 34.04 Billion by 2034 with a CAGR of 23.33%
27 mars 2024 08h50 HE
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
CAR-T Funding Report 2024: Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions
18 mars 2024 04h52 HE
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024" report has been added to ...
Global PRMT5 Targeted Therapy Market & Clinical Trials Insights 2024: Innovation and Potential in Oncology and Beyond
29 févr. 2024 04h06 HE
|
Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering. ...
France CAR-T Cell Therapy Market Anticipates Impressive Growth Amid Advances in Personalized Medicine and Increase in Hematological Malignancies
12 févr. 2024 04h32 HE
|
Research and Markets
Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "France CAR-T Cell Therapy Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has been added to ...